Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Cystic Fibrosis
Interventions: SPL84, Placebo; Drug · Other
Lead sponsor: SpliSense Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • Denver, Colorado • Boston, Massachusetts

Conditions: Corneal Edema, Corneal Defect, Corneal Transplant, Penetrating KeratoPlasty, Anterior Chamber Inflammation, Ocular Pain, Intraocular Pressure
Interventions: Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp; Drug
Lead sponsor: Nicole Fram M.D.; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cardiovascular Disease
Interventions: bococizumab (PF-04950615), Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 10,564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 518
States / cities: Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 328 more

Conditions: Plaque Psoriasis, Psoriasis Vulgaris
Interventions: Taclonex Ointment and Hydrogel Patch, Taclonex Ointment; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Age-Related Maculopathy, Age-Related Maculopathies, Eye Diseases, Retinal Degeneration, Macular Degeneration
Interventions: RN6G, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 24
States / cities: Campbell, California • Los Gatos, California • San Jose, California + 7 more

Conditions: Asthma
Interventions: Fp MDPI, Placebo MDPI, Flovent Diskus, albuterol/salbutamol; Drug · Other
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 889 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 148
States / cities: Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 114 more

Conditions: Crime, Juvenile Delinquency
Interventions: Big Brothers Big Sisters Community-Based Mentoring Program; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 10 Years and older
Enrollment: 1,361 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Submental Fat
Interventions: LIPO-202, Placebo for LIPO-202; Drug
Lead sponsor: Neothetics, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 11
States / cities: Beverly Hills, California • Manhattan Beach, California • Greenwood Village, Colorado + 8 more

Conditions: Orthostatic Hypotension, Parkinson's Disease
Interventions: Droxidopa, Placebo; Drug · Other
Lead sponsor: Chelsea Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 60
States / cities: Alabaster, Alabama • Gilbert, Arizona • Phoenix, Arizona + 53 more

Conditions: Gastroesophageal Reflux
Interventions: Nissen fundoplication; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: Up to 24 Months
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Sphincter Ani Incontinence, Obstetric Trauma
Interventions: Physical Therapy (PT) and Behavioral Therapy (BT); Behavioral
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Delirium
Interventions: Control, Preventative Delirium Protocol; Other
Lead sponsor: Rush University Medical Center; Other
Eligibility: 65 Years to 89 Years
Enrollment: 263 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Dry Eye
Interventions: OC-01 (varenicline 0.6mg/ml) nasal spray, Placebo (vehicle) Nasal Spray; Drug
Lead sponsor: Brandon Baartman; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Forehead Lines
Interventions: OnabotulinumtoxinA X, Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Newport Beach, California • Mount Kisco, New York • Rochester, New York + 4 more

Conditions: Major Depressive Disorder
Interventions: RX-10100; Drug
Lead sponsor: Rexahn Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 44
States / cities: Cerritos, California • Escondido, California • Los Angeles, California + 38 more

Conditions: Prostate Cancer
Interventions: enzastaurin, placebo, docetaxel, prednisone; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 22
States / cities: Fullerton, California • Los Angeles, California • Northridge, California + 19 more

Conditions: Chronic Kidney Disease (Stage 3-4), Vascular Function, Cognitive Functions, Cerebrovascular Function, Blood Pressure
Interventions: Equol, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years and older · Female only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Diabetes, Type I
Interventions: Technosphere Insulin, Active comparator; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 589 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 61
States / cities: Mobile, Alabama • Chandler, Arizona • Chula Vista, California + 48 more

Conditions: Hypertension, Prehypertension
Interventions: MB-BP, Enhanced Usual Care Control; Behavioral · Other
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Chronic Kidney Diseases, Vascular Function, Women
Interventions: S-equol, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years to 69 Years · Female only
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 2 Diabetes Mellitus
Interventions: Placebo, Pioglitazone, MSDC-0160 90 mg, MSDC-0160 220 mg; Drug
Lead sponsor: Metabolic Solutions Development Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Los Angeles, California • Miami Gardens, Florida • West Palm Beach, Florida + 5 more

Conditions: Bipolar Disorder
Interventions: Risperdal Consta, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 559 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 14
States / cities: Little Rock, Arkansas • La Mesa, California • National City, California + 11 more

Conditions: Diabetes Mellitus, Diabetic Nephropathy
Interventions: FG-3019; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 18
States / cities: Birmingham, Alabama • Tempe, Arizona • La Mesa, California + 15 more

Conditions: Actinic Keratoses
Interventions: ALA (5-aminolevulinic acid), Blue light therapy; Drug · Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis

Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

Randomized Controlled Trial of Big Brothers Big Sisters Mentoring for Prevention of Crime and Delinquency

Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat

A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease

Clinical Trial Comparing Open and Laparoscopic Nissen Fundoplication in Children

Physical Therapy for Women With Obstetric Trauma and Anal Incontinence

Preventative Delirium Protocol in Elderly Patients

Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Photorefractive Keratectomy (PRK)

A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants With Forehead Lines

Safety and Efficacy of RX-10100 to Treat Major Depressive Disorder

A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients

Equol and Vascular Function in Women With Chronic Kidney Disease

Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes

UH3 Phase - Mindfulness-Based Blood Pressure Reduction (MB-BP) : Stage 2a RCT

Acute Equol Supplementation and Vascular Function in Women With and Without CKD

A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator

A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes

Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy

Photodynamic Therapy Incubation Times for Actinic Keratosis